#24856
Re: Novavax (NVAX): Un Nuevo Comienzo
Son los casos por millón:
Myocarditis: 3/146300 x 1MM = 20.5
Pericarditis: 11/146300 x 1MM = 75.2
Myocarditis: 3/146300 x 1MM = 20.5
Pericarditis: 11/146300 x 1MM = 75.2
I believe tomorrow will be a normal trading day for Novavax, except possibly for a halt at 3 PM when the voting of the committee takes place...
On the other hand, if we see humongous volatility in trading tomorrow, then the company may request, and/or NASDAQ may impose, a halt of some duration...
Creo que mañana será un día de trading normal para Novavax, excepto posiblemente por una interrupción a las 3 p. m., cuando se lleve a cabo la votación del comité...
Por otro lado, si vemos una enorme volatilidad en durante la sesión mañana, entonces la empresa puede solicitar, y/o NASDAQ puede imponer, una suspensión de cierta duración...
Of the 744,235 first doses given, almost no cases of myocarditis / pericarditis occurred in Canada, the EU, New Zealand or South Korea. The only significant amount of "reports" were in Australia, but were found by the FDA to be dubious
The most important thing to be aware of is that these numbers include every possible potential myocarditis/pericarditis "report" regardless of whether any symptoms actually occurred or were made up by anti-vaxxers. This is because people can simply call a phone number and claim to suspect they have myocarditis/pericarditis (or symptoms of them), and it gets reported and added to the totals. In fact, people who post on social media saying they think they have myocarditis/pericarditis (or symptoms) are also turned into reported cases and added to the totals.
For these reasons, the Novavax FDA document says:
Spontaneous adverse event reports that are included in the Summary Safety Reports (SSRs) arise from the use of the vaccine in the real-world setting and are captured into surveillance systems similar to the FDA Vaccine Adverse Events Reporting System (VAERs), from a variety of sources, including health care providers, vaccinees, the medical literature and social media posts. However, these passive reporting systems have many limitations, including underreporting, duplicate reporting, variable report quality and accuracy, inadequate data regarding the numbers of doses administered, and lack of direct and unbiased comparison groups. These spontaneous reports may not be medically confirmed and are generally not verified.